53 results about "Mouse Colon" patented technology

The invention discloses bifidobacterium longum and the application thereof and belongs to the technical field of biologics. The invention provides a bifidobacterium longum YS108R strain which has thecharacteristic of generating viscous exopolysaccharide, and has a remarkable improvement function on DSS (Dextran Sulfate Sodium) induced mouse colitis models. The strain has a relatively good capability of enduring simulated gastrointestinal fluids, is capable of remarkably reducing disease activity indexes of mice in the DSS induction period, and has an effective protection function on colon tissue. In addition, the bifidobacterium longum YS108R disclosed by the invention is separated from intestinal florae of healthy people, is free of toxic and/or side effects on human bodies, and has certain advantages when being compared with conventional medicine treatment. The strain can be used for preparing probiotic powder, fermented milk, and the like, and has wide market prospects.

A traditional Chinese medicine composition preventing and treating colorectal precancerous lesion, a preparing method thereof and applications of the composition are disclosed. The composition includes 20-60 parts of hedyotis, 9-27 parts of lightyellow sophora root, 15-45 parts of radix codonopsis, 12-36 parts of largehead atractylodes rhizome, 12-36 parts of smoked plum, 3-9 parts of rhizoma coptidis, 6-18 parts of rhizoma zingiberis praeparatum and 30-90 parts of coix seed. Prescription screening is performed according to a traditional Chinese medicine theory that is treatment based on syndrome differentiation and according to pathogenesis of intestinal cancer. Treatment mechanisms of invigorating the spleen, benefiting qi, removing heat, drying dampness, detoxifying, removing stasis, and strengthening and consolidating body resistance are adopted innovatively. Experiment results show that the composition can obviously improve AOM-DSS induced symptoms such as body mass decrease, loose stool, and hemafecia, that the composition can reduce the occurrence rate of a colorectal lesion that is mouse colon tumor, and that the composition has significant activity resisting solid colorectal tumor and intestine cytoma. Disassembled prescription experiment results show that medicine materials of the composition are irreplaceable and the composition is a scientific prescription.

The invention relates to a medicine treating carcinoma of colon and the method for preparing the same, which in detail is aglycone extract from root of Patrinia scabra Bge and the preparation method. The effective component is iridoid glycosides aglycone, the content is above 40%. The invention also provides the medicine agent and preparation. It is proved by pharmacologia test that the medicine is characterized by safe utilization, function of preventing the weight of tumor in transplanted carcinoma of colon. The extract can be produced into preparations of tablet, capsule, drop pill, granular or oral.

The invention discloses astaxanthin nanoparticles as well as a preparation method and application thereof. The astaxanthin nanoparticles comprise 58%-68% w/w of casein, 7%-11% w/w of a chitosan-TPP compound, 24%-28% w/w of sodium alginate and 0.5%-7% w/w of astaxanthin. According to the astaxanthin nanoparticles, casein I is used for primary embedding of the astaxanthin, the chitosan-TPP compoundand the sodium alginate are further subjected to layer-by-layer self-assembly through electrostatic interaction, and pH response type and mitochondrial targeting type nanoparticles are constructed andformed. According to the method, gastric acid escape can be achieved, the release rate of the astaxanthin in intestinal tract is increased, compared with the mode that free astaxanthin can be concentrated and enriched in the colons of mice, the colitis of the mice is relieved, and the targeting effect on cell mitochondria is achieved, the embedding protection mode of the method constructs a functional characteristic nanometer carrying system, and the absorption and utilization degree of nutrients is fully improved.

The invention relates to the technical field of microorganisms, and discloses a compound bacterium agent. The compound bacterium agent is prepared from at least two of bifidobacterium longum, lactobacillus paracasei and lactobacillus plantarum. Compared with a model control group, through the compound bacterium agent, the rat gastric mucosa bleeding belt area can be significantly decreased, the gastric mucosa blood flow is increased, and the gastric mucosa damage index is decreased. The mouse colon length is significantly increased, the mouse colon tissue pathology score is decreased, and ulcerative colitis caused by intestinal mucosa damage of mice is relieved. Therefore, the probiotics compound bacterium agent has a certain gastric and intestinal mucosa protection effect, and is very suitable for preparation of food, health care products, medicines and food supplements.

The invention discloses a total nutrient formula food for inflammatory bowel diseases, and belongs to the field of formula foods for special medical purposes. The invention finds that the inflammatorybowel disease total nutrient formula food has the effect of improving the intestinal inflammatory state so as to provide nutrition support for inflammatory bowel diseases, and the effect is specifically reflected in that (1) the food has a recovery effect on the weight of mice; (2) the food has the effect of relieving mouse colonic shortening; (3) the food can reduce the activity of MPO (myeloperoxidase); and (4) the food has the effect of improving colon pathological symptoms of enteritis mice. Therefore, the inflammatory bowel disease total nutrient formula food has a huge application prospect in clinical application.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a novel pharmaceutical application of Houttuynia cordata Thunb. polysaccharide, in particular to the application of the Houttuynia cordata Thunb. polysaccharide in preparation of a medicine for preventing and treating inflammatory bowel disease (IBD). A total polysaccharide extract is separated and extracted from the traditional Chinese medicine Houttuynia cordata Thunb., the average product yield is 3.65%, and the polysaccharide content exceeds 70%. An integral experiment proves that the total polysaccharide extract of the Houttuynia cordata Thunb. has a remarkable treatment effect on mouse colonic injury induced by 2.5% DSS. The Houttuynia cordata Thunb. polysaccharide may inhibit infiltration of inflammatory cells, reduce secretion of inflammatory cytokines and inhibit expression of an inflammatory transcription factor NF [kappa] B through an anti-inflammatory mechanism of the Houttuynia cordata Thunb. polysaccharide, so that intestinal injury is reduced, intestinal mucosa is protected, and colon shortening and weight loss are relieved. The Houttuynia cordata Thunb. polysaccharide can be used for preparing medicines for preventing and treating ulcerative colitis.

The invention creatively provides an application of typhagoside in preparation of a medicine for treating inflammatory bowel diseases. According to the application disclosed by the invention, a DSS-induced C57BL/6J mouse colitis model is treated by the typhagoside. Inflammation-related parameters such as weight loss, disease activity index and spleen weight of a mouse are improved, histological staining reveals that intestinal inflammation of the mouse is inhibited, and the pathological score is reduced. By further investigating a specific mechanism of anti-inflammatory effect, the result shows that the typhagoside can inhibit activation of an NF-kB pathway in mouse intestinal epithelial cells and reduce expression of inflammatory factors in the mouse intestinal epithelial cells. In conclusion, the Chinese herbal monomer typhagoside can provide a new way for preparing medicines for treating IBD and related diseases thereof in the future.

The invention researches the anti-inflammatory activity of DSS (Dextran Sulfate Sodium) inducted colitis model for paeoniflorin and paeoniflorin metabolism pigment I. An experiment result indicates that the paeoniflorin metabolism pigment I has a good treatment effect on ulcerative colitis. Compared with a control group and a paeoniflorin group, a C57BL/6 mouse which orally takes the paeoniflorinmetabolism pigment I, the paeoniflorin metabolism pigment I is characterized in that a colon tissue damage degree is lightened, the mouse colon tissue damage degree of the low and high dosage medication administration team of the paeoniflorin metabolism pigment I is lightened, a tissue structure is clear in level, the infiltration of inherent layer inflammatory cells is reduced, the amount of cup-shaped cells is relatively increased, muscularis mucosa does not contain tissue edema and hyperaemia, and tissue forms are obviously recovered. The paeoniflorin metabolism pigment I is proved to havea good treatment effect on the ulcerative colitis.

The invention discloses application of folium perillae extracts in preparation of a medicine for treating and/or preventing the inflammatory bowel disease. The folium perillae extracts disclosed by the invention have a reverse effect on diarrhea, hematochezia, weight loss and the colon position pathological injuries of a mouse with inflammatory bowel disease induced by low molecular weight dextransulfate, can obviously inhibit secretion of model mouse colon tissue cell factors NO, IFN-gamma, IL-4, IL-10 and IL-17, and can obviously inhibit the intestinal tissue MPO level of the model mouse.

The present invention discloses an application of spermidine in preparation of medicines for treating colitis. A mouse colitis model is constructed in a model mouse, a phenotypic effect of the spermidine on mice with the colitis is studied, and the spermidine alleviates mouse inflammation-related phenotypes of weight loss, colonic shortening, hematochezia, etc.; a cell inflammatory state stimulated by TNF-alpha is constructed in human colon cancer cells in vitro, and after a spermidine treatment, inflammatory signaling pathway protein expression and downstream gene expression are obviously improved. To sum up, the spermidine improves the phenotype of the inflammation in vivo and also further proves an effect on inhibiting the inflammation through in-vitro cell experiments at a molecular level.

The invention discloses application of a nostoc commune vauch alcohol extract to preparation of medicines for treating an inflammatory bowel disease. A preparation method of the nostoc commune vauch alcohol extract comprises the following steps: taking nostoc commune vauch, using low-carbon alcohol as a solvent, extracting under a heating condition, collecting an extract, recycling the solvent toobtain the nostoc commune vauch alcohol extract. Through experiments, the applicant finds that the nostoc commune vauch alcohol extract significantly improves the weight loss of a DSS (dextran sulphate sodium)-induced UC (ulcerative colitis) model mouse, inhibits DAI (disease activity index) score increase, relieves UC-induced mouse colon length reduction and reduces inflammatory cell infiltrationand tissue damage; in addition, the nostoc commune vauch alcohol extract significantly reduces the contents of colon tissue cytokines TNF-alpha and IL-6, and such effect is closely related to activation of a key transcription factor NF-kappaB inhibiting inflammatory signaling pathways. Experimental results of the applicant show that the nostoc commune vauch alcohol extract can be used for treating the inflammatory bowel disease, relieving an inflammatory reaction of the DSS-induced UC model and improving the UC severity.

The invention belongs to the technical field of pharmacy, and relates to a novel pharmaceutical application of cinobufotalin, in particular to application of the cinobufotalin in preparation of an anti-tumor immune drug. Mouse colon cancer subcutaneous transplantation tumor model animal experiments prove that the cinobufotalin has a good effect on resisting tumor immunity, has no adverse reaction, can relieve mouse colon cancer subcutaneous tumor induced by colon cancer cells, and provides a good application prospect for treating, relieving or eliminating tumor immune escape and improving body immunity.

The invention relates to the technical field of biological medicines, firstly provides a folic acid modified Pluronic P85 copolymer and also relates to a preparation method of a 5-fluorouracil anti-cancer nano drug. Experiments show that the 5-fluorouracil nano drug prepared by adopting the folic acid modified Pluronic P85 copolymer can be used for obviously inhibiting tumour cell growth; meanwhile, in a mouse colonic carcinoma hepatic metastasis model, formation of colonic carcinoma liver metastases can be obviously reduced, and lifetime of a mouse can be obviously prolonged, so that the folic acid modified Pluronic P85 copolymer has a good effect on resisting colonic carcinoma hepatic metastasis, and the 5-fluorouracil anti-cancer nano drug is hopeful to be an anti-tumour drug with a clinical application prospect.

The invention discloses an application of a kaurane compound in preparation of a medicine for treating inflammatory bowel disease. The kaurane compound can obviously reduce the weight of a dextran sodium sulfate induced (DSS) enteritis model mouse, improve the shortening of the colon length of the colitis model mouse, relieve the infiltration of colon tissue inflammatory cells of the colitis model mouse, reduce the rise of leukocytes, neutrophils, lymphocytes and monocytes of the colitis model mouse, reduce the expression of inflammatory factors, and achieve the immunoregulation function on intestinal tracts. The mechanism of the kaurane compound may be known by adjusting polarization of macrophages and differentiation of T cells, and the kaurane compound can relieve the inflammatory reaction of DSS-induced inflammatory bowel disease model mice and improve the severity of the inflammatory bowel disease, and can be used for preparing drugs or health care products for treating the inflammatory bowel disease.

The invention discloses a benzoxazole compound as well as a preparation method, a pharmaceutical composition and application thereof. The structure of the compound is as shown in formula (I), and the compound comprises pharmaceutically acceptable salts thereof. The benzoxazole compound and the pharmaceutical composition thereof can effectively antagonize a P2Y6 receptor, the optimal in-vitro antagonism rate reaches 100%, and the optimal IC50 value reaches the picomolar concentration level; in-vivo inhibition of mouse colon length shortening, body weight reduction and DAI score increase can be realized. The compound can be used for preparing drugs for treating inflammatory diseases related to P2Y6 receptors, the prepared drugs can exert drug effects at the cellular level and the animal level, the application is wide, and the synthesis method of the compound is simple and easy to implement.

The invention provides application of Alistipes putredinis bacteria in preparation of a medicine for preventing and treating inflammatory bowel diseases, and relates to the technical field of biological medicines. A C57BL/6 mouse colitis model is adopted, and it is found that the A.putredinis bacterium can improve intestinal inflammation of DSS mice. It is confirmed for the first time that A.putredinis can inhibit intestinal inflammation of mice with DSS colitis, a new theory is provided for pathogenesis of CD, a new treatment strategy is provided for CD diagnosis and treatment, and potential clinical application prospects are achieved.

The invention belongs to the fields of genetic engineering and genetic modification of mouse cells, and particularly relates to an EpCAM gene humanized mouse tumor cell model as well as a constructionmethod and application thereof. A mouse EpCAM gene is knocked out by virtue of a CRISPR technique, and meanwhile, the humanized EpCAM gene is inserted into a mouse colon cancer cell CT26 through lentivirus infection. The EpCAM gene humanized mouse tumor cell model can be used for evaluating antibody tumor pesticide effect and has important guiding significance to clinic effects of developed drugs. Meanwhile, the EpCAM gene humanized mouse tumor cell model is an ideal mouse tumor cell model for evaluating the safety of anti-EpCAM antibody drugs and can be used for carrying out preclinical in-vivo evaluation on toxicological immunocell therapies of EpCAM antibody drugs and EpCAM-CAR T, EpCAM-CAR NK, so that a market blank is filled up.

The invention provides application of bifidobacterium longum BL21 and a microbial inoculum containing the bifidobacterium longum BL21 in preparation of products for preventing, relieving or treating colorectal cancer. The bifidobacterium longum BL21 has excellent acid-resistant and cholate-resistant capabilities and good cell adhesion capability, can improve the gene expression level of pro-apoptosis factors CASP3 and Bax and reduce the gene expression level of anti-apoptosis factors Bcl-xl and Bcl-2 by regulating the expression of genes related to apoptosis of the colorectal tumor cells of mice, induces apoptosis of the colorectal tumor cells of the mice, and can be used for preparing the bifidobacterium longum BL21. In addition, the bifidobacterium longum BL21 can be used for remarkably relieving the inflammatory response of the colon part of a colorectal cancer model mouse, relieving the oxidative stress injury of the colorectal cancer model mouse, improving the micro-ecological environment of intestinal flora and maintaining the intestinal health, so that the bifidobacterium longum BL21 can be used for remarkably relieving the inflammatory response of the colon part of the colorectal cancer model mouse. The method has a wide prospect in preparation of products for preventing or treating colorectal cancer.

The invention discloses application of silibinin in preparation of drugs for preventing and treating intestinal cancer correlated with colitis. Silibinin can reduce the occurrence rate of AOM/DSS-induced mouse colonic inflammation and colonic tumors, decrease expression of mouse colonic inflammatory factors, reduce expression of inflammatory factors in a colonic cancer cell system, alleviate damage to a colonic mucosa barrier function, decrease proliferation of mouse colonic epithelial cells and suppress proliferation of the colonic cancer cell system. By lowering IL-6/STAT3, the occurrence ofintestinal cancer correlated with colitis is suppressed. The application has a significant meaning on clinical prevention and treatment of intestinal cancer correlated with colitis, improvement of survival quality of patients and reduction of relapses of inflammation, and a new approach which is safe, effective and economical is provided for the prevention and treatment of intestinal cancer correlated with colitis.

The invention relates to application of American ginseng in forest mountain in preparation of a medicine for treating antibiotic-associated diarrhea, and belongs to the field of biomedicine. Animal model experiments are carried out by adopting an ethanol extract of the American ginseng in the forest mountain. Experimental results prove that the ethanol extract of the American ginseng under the forest mountain has a relatively good protection effect on an antibiotic-related diarrhea experimental model caused by antibiotic drug combination, and has a reversal effect on pathological changes of colon and ileum of mice; expression of proinflammatory factors TNF-alpha, IL-1beta and IL-6 in serum of mice is inhibited, so that intestinal inflammation is relieved; the level of short-chain fatty acid in the intestinal tract of the mice can be recovered; the intestinal flora structure and diversity are improved; and pains of patients can be relieved, and life quality can be improved.

The invention discloses a kojic acid and a kojic acid derivative, and a preparation method and application thereof. The invention provides a kojic acid derivative trexone A. In an anti-inflammatory activity test, the median inhibitory concentrations of the trexone A and a precursor compound kojic acid for inhibiting mouse macrophages RAW264.7 are 15.5 +/-1.2 [mu]M and 40.8 +/-3.1 [mu]M respectively, the trexone A and the kojic acid can inhibit the expression of inflammatory factors IL-1beta, IL-6, TNF-alpha and iNOS of the mouse macrophages RAW264.7, the kojic acid can be used for treating dextran sodium sulfate induced mouse colitis, the effect of the kojic acid is equivalent to that of a positive drug mesalazine, the tradone A and the kojic acid can be applied to preparation of anti-inflammatory drug precursors, and a material basis is laid for further research and application of cosmetics and medicines of anti-inflammatory drugs.

The invention belongs to the technical field of pharmacology, and discloses application of cubilose in preparation of a medicine for treating ulcerative colitis. The medicine in the application can reduce MPO activity and IL-1beta and TNF-alpha contents in colon tissues of mice, enhance the resistance of organisms to external stimulating factors, alleviate weight loss of the mice due to DSS induction, improve colitis, reduce the level of proinflammatory factors, effectively relieve symptoms and inflammatory indexes of the ulcerative colitis, and provides a new thought for the development of medicines for treating the ulcerative colitis.